Evidence-based paediatric surgical oncology

Training in Pediatric Surgical Oncology

Pediatric Surgical Oncology is a challenging sub-speciality field requiring strong discipline, resilience and a "never quit" attitude. Pediatric cancer patients are frail, vulnerable and have life limiting illness were the skill(s) of the operating surgeon may determine "cure" and survival or untimely death from inadequate tumor resection with disease progression and / or "never event" misadventure. It could be stated therefore that a career in surgical oncology may not be for the "faint hearted" surgeon. Training in a high volume center(s) accredited in the delivery of high quality care and clinical excellence driven by inspirational leaders in surgical oncology with motivated multidisciplinary teams is key. International surgery oncology fellowship(s) add significant credits to a residents' clinical training crucially also yielding opportunities for gaining research skills. On the journey toward subspeciality accreditation the aspiring surgeon oncologist must first demonstrate skill set(s) proficiency in general pediatric surgery residency training to advance to the next phase(s). This article offers a "snap shot" overview synopsis of pediatric surgical oncology training in its broadest perspective(s) for those seeking further information and career guidance.

Minimally Invasive Approaches to Pediatric Solid Tumors

Over the last decade, driven in part by the favorable adult experience and a crescendoing number of case series and retrospective reports in the pediatric surgical literature, minimally invasive surgical (MIS) approaches are increasingly used as adjunctive or definitive surgical treatments for an ever-expanding list of pediatric tumors. Although most current treatment protocols lack surgical guidelines regarding the use of MIS, this growing body of MIS literature provides a framework for the development of multicenter trial groups, prospective registries, and further centralization of subspecialist services. This article highlights the current available data on MIS approaches to a variety of pediatric malignancies.

Neuroblastoma

Neuroblastoma is one of the most common solid tumors in children and has a diverse clinical behavior that largely depends on the tumor biology. Neuroblastoma exhibits unique features, such as early age of onset, high frequency of metastatic disease at diagnosis in patients over 1 year of age and the tendency for spontaneous regression of tumors in infants. The high-risk tumors frequently have amplification of the MYCN oncogene as well as segmental chromosome alterations with poor survival. Recent advanced genomic sequencing technology has revealed that mutation of ALK, which is present in ~10% of primary tumors, often causes familial neuroblastoma with germline mutation. However, the frequency of gene mutations is relatively small and other aberrations, such as epigenetic abnormalities, have also been proposed. The risk-stratified therapy was introduced by the Japan Neuroblastoma Study Group (JNBSG), which is now moving to the Neuroblastoma Committee of Japan Children's Cancer Group (JCCG). Several clinical studies have facilitated the reduction of therapy for children with low-risk neuroblastoma disease and the significant improvement of cure rates for patients with intermediate-risk as well as high-risk disease. Therapy for patients with high-risk disease includes intensive induction chemotherapy and myeloablative chemotherapy, followed by the treatment of minimal residual disease using differentiation therapy and immunotherapy. The JCCG aims for better cures and long-term quality of life for children with cancer by facilitating new approaches targeting novel driver proteins, genetic pathways and the tumor microenvironment.

The challenges of surgical research in children

Trials in children needed